WO2004062595A3 - Antineoplastic ether lipid compounds with modifications at the sn-1 carbon - Google Patents
Antineoplastic ether lipid compounds with modifications at the sn-1 carbon Download PDFInfo
- Publication number
- WO2004062595A3 WO2004062595A3 PCT/US2004/000359 US2004000359W WO2004062595A3 WO 2004062595 A3 WO2004062595 A3 WO 2004062595A3 US 2004000359 W US2004000359 W US 2004000359W WO 2004062595 A3 WO2004062595 A3 WO 2004062595A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon
- modifications
- ether lipid
- lipid compounds
- compounds
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title abstract 2
- -1 ether lipid compounds Chemical class 0.000 title abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Ether lipid compounds of formula (I): pharmaceutically-acceptable salts, prodrugs or isomers thereof are provided, where the variables are as defined herein. The compounds of the invention have antineoplastic activity, and accordingly have utility in treating cancer and related diseases. Enantiomers of these compounds, pharmaceutical compositions, and methods for treating cancer with the pharmaceutical compositions are also provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43878703P | 2003-01-09 | 2003-01-09 | |
| US60/438,787 | 2003-01-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004062595A2 WO2004062595A2 (en) | 2004-07-29 |
| WO2004062595A3 true WO2004062595A3 (en) | 2004-12-09 |
Family
ID=32713382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/000359 WO2004062595A2 (en) | 2003-01-09 | 2004-01-09 | Antineoplastic ether lipid compounds with modifications at the sn-1 carbon |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004062595A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006019907A1 (en) * | 2006-04-28 | 2007-10-31 | Müller-Enoch, Dieter, Prof. Dr. | Use of substituted glycerin derivative in the preparation of a pharmaceutical composition for the prevention or treatment of e.g. cancer disease, pathological sequence of alcohol abuse, viral hepatitis and toxic nerve disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
-
2004
- 2004-01-09 WO PCT/US2004/000359 patent/WO2004062595A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004062595A2 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY142768A (en) | Gfat inhibitors | |
| WO2006116733A3 (en) | Protein kinase inhibitors | |
| MX2009006742A (en) | Novel compounds. | |
| EG24928A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| IS7857A (en) | Installs pyrrolo-pyrazole derivatives that inhibit kinase | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
| MY148538A (en) | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | |
| WO2005030120A3 (en) | Antiangiogenic agents | |
| WO2005004808A3 (en) | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | |
| WO2005112914A3 (en) | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | |
| WO2006089406A8 (en) | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | |
| WO2006080043A3 (en) | Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation | |
| WO2005082457A3 (en) | Use of substituted 1,2,3 indolizine derivatives for treating diseases associated with a pathological choroidal angiogenesis | |
| TNSN06233A1 (en) | 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments | |
| WO2004062593A3 (en) | Antineoplastic ether lipid compounds with modifications at the sn-2 carbon | |
| WO2004062595A3 (en) | Antineoplastic ether lipid compounds with modifications at the sn-1 carbon | |
| TW200700421A (en) | Novel triazolopyrimidine derivatives | |
| WO2004062594A3 (en) | Antineoplastic ether lipid compounds with modifications at the sn-3 carbon | |
| WO2006007508A3 (en) | Compounds and methods for treating diabetic vascular diseases | |
| WO2004062586A3 (en) | Antineoplastic ether lipid compounds | |
| WO2004062596A3 (en) | Antineoplastic ether lipid compounds having a four carbon backbone | |
| WO2002067855A3 (en) | Enantiomers of unsaturated alkyllysophosphonocholines and use as anti-neoplastics | |
| WO2004108094A3 (en) | Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |